Metoprolol Succinate Tablet, Extended Release
Product Images NDC 68071-5282

3 FDA label images from Nucare Pharmaceuticals,inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Metoprolol Succinate (NDC 68071-5282). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 5282 1)

Pdp (68071 5282 1)
Packaging label for Metoprolol Succinate 100 mg extended-release tablets from NuCare Pharmaceuticals, Inc. The label indicates a quantity of 100 tablets, provides the NDC number 68071-5282-1, instructions to see the manufacturer's label for a full list of ingredients, and warnings to keep out of reach of children and store at controlled temperature (59-86°F). Additional details include barcode information, lot number, expiration date, and reminders to consult a doctor for side effects.*
FDA Label Image

Image (8acdcf84 Bc5c 4824 85c4 D484825f00ba 01)

Image (8acdcf84 Bc5c 4824 85c4 D484825f00ba 01)
Chemical structure of metoprolol succinate depicting the molecular arrangement including functional groups and side chains, consistent with the active ingredient in METOPROLOL SUCCINATE extended-release tablets.*
FDA Label Image

Merit Hf (8acdcf84 Bc5c 4824 85c4 D484825f00ba 02)

Merit Hf (8acdcf84 Bc5c 4824 85c4 D484825f00ba 02)
A chart titled 'Results for Subgroups in MERIT-HF' showing comparative relative risk and 95% confidence intervals across multiple patient subgroups for metoprolol succinate extended-release tablets versus placebo. The three sections illustrate outcomes for total mortality, total mortality or all-cause hospitalization, and total mortality or hospitalization for heart failure, each with relative risk scales favoring either metoprolol succinate or placebo. Subgroups include geographic regions, NYHA classifications, ejection fraction levels, some clinical conditions, and demographics.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.